CA2700200A1 - Identification of novel pathways for drug development for lung disease - Google Patents
Identification of novel pathways for drug development for lung disease Download PDFInfo
- Publication number
- CA2700200A1 CA2700200A1 CA2700200A CA2700200A CA2700200A1 CA 2700200 A1 CA2700200 A1 CA 2700200A1 CA 2700200 A CA2700200 A CA 2700200A CA 2700200 A CA2700200 A CA 2700200A CA 2700200 A1 CA2700200 A1 CA 2700200A1
- Authority
- CA
- Canada
- Prior art keywords
- pathway
- activation
- individual
- biomarkers
- lung disease
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 230000037361 pathway Effects 0.000 title claims abstract description 163
- 208000019693 Lung disease Diseases 0.000 title claims abstract description 51
- 238000009509 drug development Methods 0.000 title description 2
- 230000004913 activation Effects 0.000 claims abstract description 118
- 208000020816 lung neoplasm Diseases 0.000 claims abstract description 104
- 201000005202 lung cancer Diseases 0.000 claims abstract description 98
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims abstract description 97
- 230000014509 gene expression Effects 0.000 claims abstract description 81
- 239000000090 biomarker Substances 0.000 claims abstract description 49
- 230000004650 oncogenic pathway Effects 0.000 claims abstract description 38
- 238000011282 treatment Methods 0.000 claims abstract description 34
- 108091007960 PI3Ks Proteins 0.000 claims description 195
- 238000000034 method Methods 0.000 claims description 76
- 108090000623 proteins and genes Proteins 0.000 claims description 55
- 210000004027 cell Anatomy 0.000 claims description 38
- 239000000523 sample Substances 0.000 claims description 28
- 210000001552 airway epithelial cell Anatomy 0.000 claims description 27
- 101001034652 Homo sapiens Insulin-like growth factor 1 receptor Proteins 0.000 claims description 23
- 102100039688 Insulin-like growth factor 1 receptor Human genes 0.000 claims description 23
- 239000003795 chemical substances by application Substances 0.000 claims description 21
- 238000011161 development Methods 0.000 claims description 19
- 238000002493 microarray Methods 0.000 claims description 16
- 201000010099 disease Diseases 0.000 claims description 14
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 14
- 230000003247 decreasing effect Effects 0.000 claims description 11
- 230000004044 response Effects 0.000 claims description 10
- 238000012360 testing method Methods 0.000 claims description 10
- 230000008236 biological pathway Effects 0.000 claims description 8
- 238000011144 upstream manufacturing Methods 0.000 claims description 8
- 238000002966 oligonucleotide array Methods 0.000 claims description 5
- 108091034117 Oligonucleotide Proteins 0.000 claims description 4
- 102000010400 1-phosphatidylinositol-3-kinase activity proteins Human genes 0.000 claims 15
- 230000001225 therapeutic effect Effects 0.000 abstract description 12
- 210000005058 airway cell Anatomy 0.000 abstract description 5
- 108090000430 Phosphatidylinositol 3-kinases Proteins 0.000 description 176
- 102000003993 Phosphatidylinositol 3-kinases Human genes 0.000 description 173
- 230000000694 effects Effects 0.000 description 84
- CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 description 37
- 229960000367 inositol Drugs 0.000 description 37
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 description 37
- 206010058314 Dysplasia Diseases 0.000 description 24
- 206010028980 Neoplasm Diseases 0.000 description 19
- 108090000315 Protein Kinase C Proteins 0.000 description 17
- 102000003923 Protein Kinase C Human genes 0.000 description 17
- 230000018109 developmental process Effects 0.000 description 17
- 238000013459 approach Methods 0.000 description 15
- 238000004458 analytical method Methods 0.000 description 14
- 210000000981 epithelium Anatomy 0.000 description 14
- 238000000338 in vitro Methods 0.000 description 14
- 230000003321 amplification Effects 0.000 description 13
- 238000013276 bronchoscopy Methods 0.000 description 13
- 238000003199 nucleic acid amplification method Methods 0.000 description 13
- 239000000047 product Substances 0.000 description 13
- 210000001519 tissue Anatomy 0.000 description 13
- 230000001680 brushing effect Effects 0.000 description 11
- 230000002596 correlated effect Effects 0.000 description 11
- 230000003902 lesion Effects 0.000 description 11
- 230000006378 damage Effects 0.000 description 10
- 230000003831 deregulation Effects 0.000 description 10
- 239000000779 smoke Substances 0.000 description 10
- 210000004072 lung Anatomy 0.000 description 9
- 208000037841 lung tumor Diseases 0.000 description 9
- 230000007170 pathology Effects 0.000 description 9
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 8
- 239000007983 Tris buffer Substances 0.000 description 8
- 201000011510 cancer Diseases 0.000 description 8
- 108020004999 messenger RNA Proteins 0.000 description 8
- 230000003632 chemoprophylactic effect Effects 0.000 description 7
- 230000001186 cumulative effect Effects 0.000 description 7
- 108020004707 nucleic acids Proteins 0.000 description 7
- 102000039446 nucleic acids Human genes 0.000 description 7
- 150000007523 nucleic acids Chemical class 0.000 description 7
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 7
- 208000005623 Carcinogenesis Diseases 0.000 description 6
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 6
- 241000124008 Mammalia Species 0.000 description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- 241000283973 Oryctolagus cuniculus Species 0.000 description 6
- 238000003491 array Methods 0.000 description 6
- 230000036952 cancer formation Effects 0.000 description 6
- 231100000504 carcinogenesis Toxicity 0.000 description 6
- 235000019504 cigarettes Nutrition 0.000 description 6
- 238000001514 detection method Methods 0.000 description 6
- 210000002919 epithelial cell Anatomy 0.000 description 6
- 238000009396 hybridization Methods 0.000 description 6
- 239000003112 inhibitor Substances 0.000 description 6
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 6
- 230000035772 mutation Effects 0.000 description 6
- 102000004169 proteins and genes Human genes 0.000 description 6
- 239000011780 sodium chloride Substances 0.000 description 6
- 238000012549 training Methods 0.000 description 6
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 5
- 101000904150 Homo sapiens Transcription factor E2F3 Proteins 0.000 description 5
- 102100024027 Transcription factor E2F3 Human genes 0.000 description 5
- 208000027418 Wounds and injury Diseases 0.000 description 5
- 239000012472 biological sample Substances 0.000 description 5
- 239000000872 buffer Substances 0.000 description 5
- 230000005754 cellular signaling Effects 0.000 description 5
- 239000002299 complementary DNA Substances 0.000 description 5
- 230000007423 decrease Effects 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 238000011223 gene expression profiling Methods 0.000 description 5
- 230000036541 health Effects 0.000 description 5
- 238000001727 in vivo Methods 0.000 description 5
- 208000014674 injury Diseases 0.000 description 5
- 230000002246 oncogenic effect Effects 0.000 description 5
- 238000003752 polymerase chain reaction Methods 0.000 description 5
- 210000002345 respiratory system Anatomy 0.000 description 5
- 230000002441 reversible effect Effects 0.000 description 5
- 230000019491 signal transduction Effects 0.000 description 5
- 101100297694 Arabidopsis thaliana PIP2-7 gene Proteins 0.000 description 4
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- 102100025064 Cellular tumor antigen p53 Human genes 0.000 description 4
- 102000038030 PI3Ks Human genes 0.000 description 4
- 108091000080 Phosphotransferase Proteins 0.000 description 4
- 229920001213 Polysorbate 20 Polymers 0.000 description 4
- 101100456541 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) MEC3 gene Proteins 0.000 description 4
- 101100483663 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) UFD1 gene Proteins 0.000 description 4
- 238000001574 biopsy Methods 0.000 description 4
- 230000002074 deregulated effect Effects 0.000 description 4
- 238000000021 kinase assay Methods 0.000 description 4
- 230000007246 mechanism Effects 0.000 description 4
- 238000010369 molecular cloning Methods 0.000 description 4
- 102000020233 phosphotransferase Human genes 0.000 description 4
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 4
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 4
- 230000001855 preneoplastic effect Effects 0.000 description 4
- 102000016914 ras Proteins Human genes 0.000 description 4
- 230000009467 reduction Effects 0.000 description 4
- 230000000391 smoking effect Effects 0.000 description 4
- 238000001262 western blot Methods 0.000 description 4
- 208000010507 Adenocarcinoma of Lung Diseases 0.000 description 3
- 102000004877 Insulin Human genes 0.000 description 3
- 108090001061 Insulin Proteins 0.000 description 3
- 150000001413 amino acids Chemical class 0.000 description 3
- 238000000376 autoradiography Methods 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 238000004113 cell culture Methods 0.000 description 3
- 230000007120 differential activation Effects 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 229940125396 insulin Drugs 0.000 description 3
- 238000007834 ligase chain reaction Methods 0.000 description 3
- 201000005249 lung adenocarcinoma Diseases 0.000 description 3
- 230000003211 malignant effect Effects 0.000 description 3
- 230000010534 mechanism of action Effects 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 238000012544 monitoring process Methods 0.000 description 3
- 239000002773 nucleotide Substances 0.000 description 3
- 125000003729 nucleotide group Chemical group 0.000 description 3
- 231100000590 oncogenic Toxicity 0.000 description 3
- 230000026731 phosphorylation Effects 0.000 description 3
- 238000006366 phosphorylation reaction Methods 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 108010014186 ras Proteins Proteins 0.000 description 3
- 238000012216 screening Methods 0.000 description 3
- 230000011664 signaling Effects 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 238000011269 treatment regimen Methods 0.000 description 3
- IHIXIJGXTJIKRB-UHFFFAOYSA-N trisodium vanadate Chemical compound [Na+].[Na+].[Na+].[O-][V]([O-])([O-])=O IHIXIJGXTJIKRB-UHFFFAOYSA-N 0.000 description 3
- 241000701161 unidentified adenovirus Species 0.000 description 3
- 238000010200 validation analysis Methods 0.000 description 3
- 206010069754 Acquired gene mutation Diseases 0.000 description 2
- 206010006187 Breast cancer Diseases 0.000 description 2
- 208000026310 Breast neoplasm Diseases 0.000 description 2
- 108020004414 DNA Proteins 0.000 description 2
- 101100239628 Danio rerio myca gene Proteins 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 description 2
- 102100037852 Insulin-like growth factor I Human genes 0.000 description 2
- 101150039798 MYC gene Proteins 0.000 description 2
- 238000000585 Mann–Whitney U test Methods 0.000 description 2
- 241000208125 Nicotiana Species 0.000 description 2
- 235000002637 Nicotiana tabacum Nutrition 0.000 description 2
- 239000000020 Nitrocellulose Substances 0.000 description 2
- 239000012083 RIPA buffer Substances 0.000 description 2
- 238000011529 RT qPCR Methods 0.000 description 2
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 description 2
- 101150001535 SRC gene Proteins 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 2
- 101100459258 Xenopus laevis myc-a gene Proteins 0.000 description 2
- 230000003213 activating effect Effects 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 238000011325 biochemical measurement Methods 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 210000000424 bronchial epithelial cell Anatomy 0.000 description 2
- 230000003197 catalytic effect Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 238000000354 decomposition reaction Methods 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 231100000673 dose–response relationship Toxicity 0.000 description 2
- 239000012636 effector Substances 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 238000010199 gene set enrichment analysis Methods 0.000 description 2
- 230000004547 gene signature Effects 0.000 description 2
- 238000003205 genotyping method Methods 0.000 description 2
- 210000004602 germ cell Anatomy 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- KWGKDLIKAYFUFQ-UHFFFAOYSA-M lithium chloride Chemical compound [Li+].[Cl-] KWGKDLIKAYFUFQ-UHFFFAOYSA-M 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 229920001220 nitrocellulos Polymers 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 239000013610 patient sample Substances 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 2
- 150000003905 phosphatidylinositols Chemical class 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 230000010076 replication Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 238000003196 serial analysis of gene expression Methods 0.000 description 2
- QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 description 2
- 229960002930 sirolimus Drugs 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 230000037439 somatic mutation Effects 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 239000013589 supplement Substances 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- 230000004614 tumor growth Effects 0.000 description 2
- WZUVPPKBWHMQCE-XJKSGUPXSA-N (+)-haematoxylin Chemical compound C12=CC(O)=C(O)C=C2C[C@]2(O)[C@H]1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-XJKSGUPXSA-N 0.000 description 1
- 108020005544 Antisense RNA Proteins 0.000 description 1
- 108060000903 Beta-catenin Proteins 0.000 description 1
- 102000015735 Beta-catenin Human genes 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 238000009010 Bradford assay Methods 0.000 description 1
- 206010057004 Bronchial dysplasia Diseases 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 108091035707 Consensus sequence Proteins 0.000 description 1
- 230000004544 DNA amplification Effects 0.000 description 1
- 230000007067 DNA methylation Effects 0.000 description 1
- 238000000018 DNA microarray Methods 0.000 description 1
- SHIBSTMRCDJXLN-UHFFFAOYSA-N Digoxigenin Natural products C1CC(C2C(C3(C)CCC(O)CC3CC2)CC2O)(O)C2(C)C1C1=CC(=O)OC1 SHIBSTMRCDJXLN-UHFFFAOYSA-N 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 208000034826 Genetic Predisposition to Disease Diseases 0.000 description 1
- 102100031181 Glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 1
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Natural products C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 1
- 102100026122 High affinity immunoglobulin gamma Fc receptor I Human genes 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101100066427 Homo sapiens FCGR1A gene Proteins 0.000 description 1
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 1
- 238000012404 In vitro experiment Methods 0.000 description 1
- 102000003746 Insulin Receptor Human genes 0.000 description 1
- 108010001127 Insulin Receptor Proteins 0.000 description 1
- 102000011782 Keratins Human genes 0.000 description 1
- 108010076876 Keratins Proteins 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- 238000000636 Northern blotting Methods 0.000 description 1
- -1 Np63 Proteins 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- 108700020796 Oncogene Proteins 0.000 description 1
- 102000014160 PTEN Phosphohydrolase Human genes 0.000 description 1
- 108010011536 PTEN Phosphohydrolase Proteins 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 208000006994 Precancerous Conditions Diseases 0.000 description 1
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 1
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 1
- 102100033810 RAC-alpha serine/threonine-protein kinase Human genes 0.000 description 1
- 102000006382 Ribonucleases Human genes 0.000 description 1
- 108010083644 Ribonucleases Proteins 0.000 description 1
- 239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 1
- 229920002684 Sepharose Polymers 0.000 description 1
- 206010040067 Septic embolus Diseases 0.000 description 1
- 101710120037 Toxin CcdB Proteins 0.000 description 1
- 102100027881 Tumor protein 63 Human genes 0.000 description 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
- 230000001594 aberrant effect Effects 0.000 description 1
- 239000011543 agarose gel Substances 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 238000012742 biochemical analysis Methods 0.000 description 1
- 238000010256 biochemical assay Methods 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000000621 bronchi Anatomy 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 230000002113 chemopreventative effect Effects 0.000 description 1
- 230000002759 chromosomal effect Effects 0.000 description 1
- 239000003184 complementary RNA Substances 0.000 description 1
- 238000010205 computational analysis Methods 0.000 description 1
- 238000000205 computational method Methods 0.000 description 1
- 238000004590 computer program Methods 0.000 description 1
- 230000006552 constitutive activation Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 238000010219 correlation analysis Methods 0.000 description 1
- 230000000875 corresponding effect Effects 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 238000000326 densiometry Methods 0.000 description 1
- 229960003964 deoxycholic acid Drugs 0.000 description 1
- KXGVEGMKQFWNSR-LLQZFEROSA-N deoxycholic acid Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 KXGVEGMKQFWNSR-LLQZFEROSA-N 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 239000000104 diagnostic biomarker Substances 0.000 description 1
- QONQRTHLHBTMGP-UHFFFAOYSA-N digitoxigenin Natural products CC12CCC(C3(CCC(O)CC3CC3)C)C3C11OC1CC2C1=CC(=O)OC1 QONQRTHLHBTMGP-UHFFFAOYSA-N 0.000 description 1
- SHIBSTMRCDJXLN-KCZCNTNESA-N digoxigenin Chemical compound C1([C@@H]2[C@@]3([C@@](CC2)(O)[C@H]2[C@@H]([C@@]4(C)CC[C@H](O)C[C@H]4CC2)C[C@H]3O)C)=CC(=O)OC1 SHIBSTMRCDJXLN-KCZCNTNESA-N 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- IRXRGVFLQOSHOH-UHFFFAOYSA-L dipotassium;oxalate Chemical compound [K+].[K+].[O-]C(=O)C([O-])=O IRXRGVFLQOSHOH-UHFFFAOYSA-L 0.000 description 1
- 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 description 1
- 230000006806 disease prevention Effects 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- 238000007876 drug discovery Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 description 1
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 description 1
- 238000010195 expression analysis Methods 0.000 description 1
- 239000012091 fetal bovine serum Substances 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 238000011331 genomic analysis Methods 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 238000007901 in situ hybridization Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 210000003292 kidney cell Anatomy 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 238000012153 long-term therapy Methods 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 235000020121 low-fat milk Nutrition 0.000 description 1
- 210000005265 lung cell Anatomy 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 239000012139 lysis buffer Substances 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 208000037819 metastatic cancer Diseases 0.000 description 1
- 208000011575 metastatic malignant neoplasm Diseases 0.000 description 1
- 238000010208 microarray analysis Methods 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 108010093336 myo-inositol D-3 hydroxykinase Proteins 0.000 description 1
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 description 1
- 238000003499 nucleic acid array Methods 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
- 238000001558 permutation test Methods 0.000 description 1
- 239000000902 placebo Substances 0.000 description 1
- 229940068196 placebo Drugs 0.000 description 1
- 108091033319 polynucleotide Proteins 0.000 description 1
- 102000040430 polynucleotide Human genes 0.000 description 1
- 239000002157 polynucleotide Substances 0.000 description 1
- 238000002203 pretreatment Methods 0.000 description 1
- 238000000751 protein extraction Methods 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 238000010188 recombinant method Methods 0.000 description 1
- 230000004043 responsiveness Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 238000005464 sample preparation method Methods 0.000 description 1
- 201000000306 sarcoidosis Diseases 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 230000007781 signaling event Effects 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 238000002626 targeted therapy Methods 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 230000005748 tumor development Effects 0.000 description 1
- 230000003827 upregulation Effects 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 238000012800 visualization Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/047—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/48—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase
- C12Q1/485—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase involving kinase
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6809—Methods for determination or identification of nucleic acids involving differential detection
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57423—Specifically defined cancers of lung
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/16—Primer sets for multiplex assays
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/91—Transferases (2.)
- G01N2333/912—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
- G01N2333/91205—Phosphotransferases in general
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/50—Determining the risk of developing a disease
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/70—Mechanisms involved in disease identification
- G01N2800/7023—(Hyper)proliferation
- G01N2800/7028—Cancer
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Analytical Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Genetics & Genomics (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Physics & Mathematics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pathology (AREA)
- General Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Hospice & Palliative Care (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Cell Biology (AREA)
- Food Science & Technology (AREA)
- General Physics & Mathematics (AREA)
- Pulmonology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US99464307P | 2007-09-19 | 2007-09-19 | |
| US60/994,643 | 2007-09-19 | ||
| PCT/US2008/077136 WO2009039457A1 (en) | 2007-09-19 | 2008-09-19 | Identification of novel pathways for drug development for lung disease |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2700200A1 true CA2700200A1 (en) | 2009-03-26 |
Family
ID=40468411
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2700200A Abandoned CA2700200A1 (en) | 2007-09-19 | 2008-09-19 | Identification of novel pathways for drug development for lung disease |
Country Status (7)
| Country | Link |
|---|---|
| US (3) | US20090186951A1 (enExample) |
| EP (1) | EP2193211A4 (enExample) |
| JP (2) | JP2010538680A (enExample) |
| CN (1) | CN101990577A (enExample) |
| AU (1) | AU2008302076B2 (enExample) |
| CA (1) | CA2700200A1 (enExample) |
| WO (1) | WO2009039457A1 (enExample) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005047451A2 (en) * | 2003-11-12 | 2005-05-26 | Trustees Of Boston University | Isolation of nucleic acid from mouth epithelial cells |
| EP1874962A2 (en) * | 2005-04-14 | 2008-01-09 | The Trustees Of Boston University | Diagnostic for lung disorders using class prediction |
| EP2605018A1 (en) * | 2006-03-09 | 2013-06-19 | The Trustees of the Boston University | Diagnostic and prognostic methods for lung disorders using gene expression profiles from nose epithelial cells |
| PE20090368A1 (es) | 2007-06-19 | 2009-04-28 | Boehringer Ingelheim Int | Anticuerpos anti-igf |
| CN101990577A (zh) | 2007-09-19 | 2011-03-23 | 波士顿大学理事会 | 鉴定肺病药物开发的新途径 |
| WO2009121070A1 (en) * | 2008-03-28 | 2009-10-01 | The Trustees Of Boston University | Multifactorial methods for detecting lung disorders |
| US10236078B2 (en) | 2008-11-17 | 2019-03-19 | Veracyte, Inc. | Methods for processing or analyzing a sample of thyroid tissue |
| US9495515B1 (en) | 2009-12-09 | 2016-11-15 | Veracyte, Inc. | Algorithms for disease diagnostics |
| CN103396487A (zh) | 2008-12-12 | 2013-11-20 | 贝林格尔.英格海姆国际有限公司 | 抗igf抗体 |
| JP6078339B2 (ja) | 2009-05-07 | 2017-02-08 | ベラサイト インコーポレイテッド | 甲状腺状態の診断のための方法および組成物 |
| WO2011133867A2 (en) * | 2010-04-23 | 2011-10-27 | The Regents Of The University Of Colorado, A Body Corporate | Vaccines, methods of administering vaccines, methods and products for treating and/or delaying onset of dysplastic lesions, and wafers for oral administration |
| WO2012130720A2 (en) * | 2011-03-28 | 2012-10-04 | Cemm - Forschungszentrum Für Molekulare Medizin Gmbh | PREDICTION OF RESPONSIVENESS TO PIK3/mTOR INHIBITORS |
| WO2012135651A1 (en) | 2011-03-31 | 2012-10-04 | The Procter & Gamble Company | Systems, models and methods for identifying and evaluating skin-active agents effective for treating dandruff/seborrheic dermatitis |
| WO2013177060A2 (en) * | 2012-05-20 | 2013-11-28 | Trustees Of Boston University | Methods and systems for monitoring, diagnosing, and treating chronic obstructive polmonary disease |
| US9920357B2 (en) | 2012-06-06 | 2018-03-20 | The Procter & Gamble Company | Systems and methods for identifying cosmetic agents for hair/scalp care compositions |
| WO2013190092A1 (en) | 2012-06-21 | 2013-12-27 | Philip Morris Products S.A. | Gene signatures for copd diagnosis |
| US20140255413A1 (en) | 2013-03-07 | 2014-09-11 | Boehringer Ingelheim International Gmbh | Combination therapy for neoplasia treatment |
| US10526655B2 (en) | 2013-03-14 | 2020-01-07 | Veracyte, Inc. | Methods for evaluating COPD status |
| US11976329B2 (en) | 2013-03-15 | 2024-05-07 | Veracyte, Inc. | Methods and systems for detecting usual interstitial pneumonia |
| WO2016011068A1 (en) | 2014-07-14 | 2016-01-21 | Allegro Diagnostics Corp. | Methods for evaluating lung cancer status |
| US12297505B2 (en) | 2014-07-14 | 2025-05-13 | Veracyte, Inc. | Algorithms for disease diagnostics |
| EP3770274A1 (en) | 2014-11-05 | 2021-01-27 | Veracyte, Inc. | Systems and methods of diagnosing idiopathic pulmonary fibrosis on transbronchial biopsies using machine learning and high dimensional transcriptional data |
| US10927417B2 (en) | 2016-07-08 | 2021-02-23 | Trustees Of Boston University | Gene expression-based biomarker for the detection and monitoring of bronchial premalignant lesions |
Family Cites Families (64)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3640268A (en) * | 1965-10-23 | 1972-02-08 | Hugh J Davis | Method and device for biopsy specimen collecting and handling |
| US4641662A (en) * | 1984-09-28 | 1987-02-10 | Jaicks John R | Endocervical curette system |
| US4800896A (en) * | 1985-11-08 | 1989-01-31 | Jalowayski Alfredo A | Cell sample collector probe |
| US5726060A (en) | 1991-09-17 | 1998-03-10 | Bridges; Michael Anthony | Method for culturing mammalian respiratory epithelial cells |
| US5422273A (en) * | 1993-03-23 | 1995-06-06 | Baal Medical Products, Inc. | Cell collection apparatus |
| US5876978A (en) | 1993-04-06 | 1999-03-02 | Medical College Of Ohio | Method for quantitative measurement of gene expression using multiplex competitive reverse transcriptase-polymerase chain reaction |
| US5477863A (en) * | 1993-04-14 | 1995-12-26 | Grant; Michael A. | Collection kit with a sample collector |
| US5440942A (en) * | 1994-02-02 | 1995-08-15 | Hubbard; Stephen H. | Biological sample collecting and holding device |
| US5795782A (en) | 1995-03-17 | 1998-08-18 | President & Fellows Of Harvard College | Characterization of individual polymer molecules based on monomer-interface interactions |
| US6085907A (en) * | 1998-05-08 | 2000-07-11 | Institute Of Legal Medicine, University Of Bern | Foldable cardboard box for contact-free drying and long-term storage of biological evidence recovered on cotton swabs and forensic evidence collection kit including same |
| CA2328138A1 (en) | 1998-05-21 | 1999-11-25 | Diadexus Llc | A novel method of diagnosing, monitoring, and staging lung cancer |
| US6204375B1 (en) | 1998-07-31 | 2001-03-20 | Ambion, Inc. | Methods and reagents for preserving RNA in cell and tissue samples |
| US20040241728A1 (en) * | 1999-01-06 | 2004-12-02 | Chondrogene Limited | Method for the detection of lung disease related gene transcripts in blood |
| US6746846B1 (en) * | 1999-06-30 | 2004-06-08 | Corixa Corporation | Methods for diagnosing lung cancer |
| AU7808500A (en) | 1999-10-18 | 2001-04-30 | Denis Marshall-Fraser | Sample taking device |
| US6383804B1 (en) | 2000-07-13 | 2002-05-07 | International Bioproducts, Inc. | Sampling device with snap-off head and method of use |
| AU2001281136A1 (en) | 2000-08-04 | 2002-02-18 | Board Of Regents, The University Of Texas System | Detection and diagnosis of smoking related cancers |
| US20020160388A1 (en) | 2000-11-20 | 2002-10-31 | Roberto Macina | Compositions and methods relating to lung specific genes and proteins |
| WO2002044331A2 (en) | 2000-11-29 | 2002-06-06 | Cangen International | Dap-kinase and hoxa9, two human genes associated with genesis, progression, and aggressiveness of non-small cell lung cancer |
| US6972181B2 (en) | 2001-01-12 | 2005-12-06 | Mount Sinai School Of Medicine Of New York University | Differential diagnosis of cancer and other conditions based on expression of p63 |
| WO2003040325A2 (en) | 2001-02-01 | 2003-05-15 | Curagen Corporation | Novel proteins and nucleic acids encoding same |
| IL157872A0 (en) * | 2001-03-12 | 2004-03-28 | Monogen Inc | A panel for detecting a generic disease state containing a plurality of probes and using cell-based diagnosis |
| AU2002250285A1 (en) * | 2001-03-14 | 2002-09-24 | Medical College Of Ohio | Method for quantitative measurement of gene expression for identifying individuals at risk for bronchogenic carcinoma |
| AU2002309583A1 (en) | 2001-04-18 | 2002-11-05 | Protein Desing Labs, Inc. | Methods of diagnosis of lung cancer, compositions and methods of screening for modulators of lung cancer |
| US7332590B2 (en) | 2001-08-16 | 2008-02-19 | The United States Of America As Represented By The Department Of Health And Human Services | Molecular characteristics of non-small cell lung cancer |
| AU2002343443A1 (en) * | 2001-09-28 | 2003-04-14 | Whitehead Institute For Biomedical Research | Classification of lung carcinomas using gene expression analysis |
| US20040005294A1 (en) * | 2002-02-25 | 2004-01-08 | Ho-Young Lee | IGFBP-3 in the diagnosis and treatment of cancer |
| US8722331B2 (en) * | 2002-03-28 | 2014-05-13 | University Of Toledo | Method for selecting a treatment for non-small cell lung cancer using gene expression profiles |
| DE10219117C1 (de) | 2002-04-29 | 2003-10-30 | Adnagen Ag | Verfahren zur Stabilisierung von RNS und Verwendungen von Stabilisierungspuffern |
| US20040063120A1 (en) * | 2002-07-10 | 2004-04-01 | The Regents Of The University Of Michigan | Expression profile of lung cancer |
| PT2042504E (pt) | 2002-09-30 | 2011-09-07 | Bayer Schering Pharma Ag | Derivados da azolepirimidina fundida |
| WO2004070062A2 (en) * | 2003-02-04 | 2004-08-19 | Wyeth | Compositions and methods for diagnosing and treating cancers |
| US20040241725A1 (en) * | 2003-03-25 | 2004-12-02 | Wenming Xiao | Lung cancer detection |
| WO2004091511A2 (en) | 2003-04-10 | 2004-10-28 | Genzyme Corporation | Compositions and methods to diagnose and treat lung cancer |
| WO2005000098A2 (en) | 2003-06-10 | 2005-01-06 | The Trustees Of Boston University | Detection methods for disorders of the lung |
| WO2004111197A2 (en) | 2003-06-10 | 2004-12-23 | Trustees Of Boston University | Gene expression signatures, methods and compositions for diagnosing disorders of the lung |
| WO2005047451A2 (en) * | 2003-11-12 | 2005-05-26 | Trustees Of Boston University | Isolation of nucleic acid from mouth epithelial cells |
| EP1753873A4 (en) * | 2004-03-05 | 2008-11-05 | Ohio Med College | METHOD AND COMPOSITIONS FOR THE ASSESSMENT OF NUCLEIC ACIDS AND ALLELES |
| WO2006056080A1 (en) | 2004-11-29 | 2006-06-01 | Diagnocure Inc. | Gpx2 a specific and sensitive target for lung cancer diagnosis, prognosis and/or theranosis |
| ES2356830T3 (es) * | 2004-12-03 | 2011-04-13 | Schering Corporation | Biomarcadores para preselección de pacientes para terapia de anti-igf-1r. |
| US7862995B2 (en) * | 2004-12-10 | 2011-01-04 | Targeted Molecular Diagnostics | Methods and materials for predicting responsiveness to treatment with dual tyrosine kinase inhibitor |
| EP1851334A4 (en) * | 2005-01-21 | 2010-05-26 | Gene Express Inc | DATABASES FOR EVALUATING NUCLEIC ACIDS |
| EP1874962A2 (en) | 2005-04-14 | 2008-01-09 | The Trustees Of Boston University | Diagnostic for lung disorders using class prediction |
| EP1940860B1 (en) * | 2005-09-02 | 2012-08-08 | The University of Toledo | Methods for identifying biomarkers useful in diagnosis and/or treatment of biological states |
| EP2605018A1 (en) | 2006-03-09 | 2013-06-19 | The Trustees of the Boston University | Diagnostic and prognostic methods for lung disorders using gene expression profiles from nose epithelial cells |
| US7832459B2 (en) | 2007-08-30 | 2010-11-16 | Phillips Plastics Corporation | Methods, tools, and products for molded ordered porous structures |
| CN101990577A (zh) | 2007-09-19 | 2011-03-23 | 波士顿大学理事会 | 鉴定肺病药物开发的新途径 |
| US20090246779A1 (en) | 2008-02-15 | 2009-10-01 | University Of Washington | Increasing genomic instability during premalignant neoplastic progression revealed through high resolution array-cgh |
| WO2009121070A1 (en) | 2008-03-28 | 2009-10-01 | The Trustees Of Boston University | Multifactorial methods for detecting lung disorders |
| WO2010054233A1 (en) | 2008-11-08 | 2010-05-14 | The Wistar Institute Of Anatomy And Biology | Biomarkers in peripheral blood mononuclear cells for diagnosing or detecting lung cancers |
| US8735074B2 (en) | 2009-08-28 | 2014-05-27 | Asuragen, Inc. | MiRNA biomarkers of lung disease |
| US20130303826A1 (en) | 2011-01-11 | 2013-11-14 | University Health Network | Prognostic signature for oral squamous cell carcinoma |
| US20120288860A1 (en) | 2011-05-12 | 2012-11-15 | George Mason University | Differential gene expression for detecting and/or differentiating lung disease |
| WO2013033640A1 (en) | 2011-09-01 | 2013-03-07 | Allegro Diagnostics Corp. | Methods and compositions for detecting cancer based on mirna expression profiles |
| WO2013049152A2 (en) | 2011-09-26 | 2013-04-04 | Allegro Diagnostics Corp. | Methods for evaluating lung cancer status |
| WO2013134786A2 (en) | 2012-03-09 | 2013-09-12 | Caris Life Sciences Luxembourg Holdings, S.A.R.L. | Biomarker compositions and methods |
| WO2013163568A2 (en) | 2012-04-26 | 2013-10-31 | Allegro Diagnostics Corp. | Methods for evaluating lung cancer status |
| WO2013177060A2 (en) | 2012-05-20 | 2013-11-28 | Trustees Of Boston University | Methods and systems for monitoring, diagnosing, and treating chronic obstructive polmonary disease |
| US10526655B2 (en) | 2013-03-14 | 2020-01-07 | Veracyte, Inc. | Methods for evaluating COPD status |
| EP2971128B1 (en) | 2013-03-15 | 2023-03-01 | Veracyte, Inc. | Biomarkers for diagnosis of lung diseases and methods of use thereof |
| WO2016011068A1 (en) | 2014-07-14 | 2016-01-21 | Allegro Diagnostics Corp. | Methods for evaluating lung cancer status |
| US20190292600A1 (en) | 2016-05-12 | 2019-09-26 | Trustees Of Boston University | Nasal epithelium gene expression signature and classifier for the prediction of lung cancer |
| US10927417B2 (en) | 2016-07-08 | 2021-02-23 | Trustees Of Boston University | Gene expression-based biomarker for the detection and monitoring of bronchial premalignant lesions |
| AU2017324949B2 (en) | 2016-09-07 | 2024-05-23 | Veracyte, Inc. | Methods and systems for detecting usual interstitial pneumonia |
-
2008
- 2008-09-19 CN CN2008801147951A patent/CN101990577A/zh active Pending
- 2008-09-19 JP JP2010526034A patent/JP2010538680A/ja active Pending
- 2008-09-19 WO PCT/US2008/077136 patent/WO2009039457A1/en not_active Ceased
- 2008-09-19 EP EP20080832403 patent/EP2193211A4/en not_active Withdrawn
- 2008-09-19 CA CA2700200A patent/CA2700200A1/en not_active Abandoned
- 2008-09-19 US US12/234,588 patent/US20090186951A1/en not_active Abandoned
- 2008-09-19 AU AU2008302076A patent/AU2008302076B2/en not_active Ceased
-
2014
- 2014-07-31 JP JP2014155833A patent/JP2014204737A/ja active Pending
- 2014-09-29 US US14/500,475 patent/US10570454B2/en active Active
-
2020
- 2020-01-23 US US16/751,145 patent/US20200232045A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| AU2008302076A1 (en) | 2009-03-26 |
| CN101990577A (zh) | 2011-03-23 |
| EP2193211A4 (en) | 2010-12-08 |
| EP2193211A1 (en) | 2010-06-09 |
| US20200232045A1 (en) | 2020-07-23 |
| JP2010538680A (ja) | 2010-12-16 |
| JP2014204737A (ja) | 2014-10-30 |
| US20150232945A1 (en) | 2015-08-20 |
| AU2008302076B2 (en) | 2015-06-11 |
| US20090186951A1 (en) | 2009-07-23 |
| US10570454B2 (en) | 2020-02-25 |
| WO2009039457A1 (en) | 2009-03-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20200232045A1 (en) | Methods of identifying individuals at increased risk of lung cancer | |
| Borczuk et al. | Lung adenocarcinoma global profiling identifies type II transforming growth factor-β receptor as a repressor of invasiveness | |
| Lei et al. | Anaplastic lymphoma kinase variants and the percentage of ALK-positive tumor cells and the efficacy of crizotinib in advanced NSCLC | |
| US20180051344A1 (en) | Embryonic isoforms of gata6 and nkx2-1 for use in lung cancer diagnosis | |
| EP3186394B1 (en) | Detection of melanoma | |
| US8455196B2 (en) | Biomarker for identifying subgroup of early-stage lung adenocarcinoma patients | |
| Chüeh et al. | CSK-homologous kinase (CHK/MATK) is a potential colorectal cancer tumour suppressor gene epigenetically silenced by promoter methylation | |
| Sahu et al. | New advances in molecular approaches to head and neck squamous cell carcinoma | |
| Wu et al. | Combining the tyrosine kinase inhibitor cabozantinib and the mTORC1/2 inhibitor sapanisertib blocks ERK pathway activity and suppresses tumor growth in renal cell carcinoma | |
| Yang et al. | K-ras Mutational Status in Cytohistological Tissue as a Molecular Marker for the Diagnosis of Pancreatic Cancer: A Systematic Review and Meta‐Analysis | |
| Kim et al. | KIF5B-RET Fusion gene may coincide oncogenic mutations of EGFR or KRAS gene in lung adenocarcinomas | |
| WO2010015538A2 (en) | Predictive marker for egfr inhibitor treatment | |
| Zhang et al. | Combined expression of the BRAFV600E mutation and PD-L1 in early papillary thyroid carcinoma and its relationship with clinicopathological features and recurrence—a retrospective cohort study | |
| WO2018095933A1 (en) | Method of prognosticating, or for determining the efficiency of a compound for treating cancer | |
| US9528982B2 (en) | Bad phosphorylation determines ovarian cancer chemo-sensitivity and patient survival | |
| US20250305055A1 (en) | Prognostic/predictive breast cancer signature | |
| US20240226074A1 (en) | Cell-of-origin targeted drug repurposing for triple-negative and inflammatory breast carcinoma with hdac and hsp90 inhibitors combined with niclosamide | |
| Ma et al. | NSUN6, a gene related with m5c methylation, may serve as a biomarker for pan-cancer | |
| Rongyue et al. | High expression of SMPD4 promotes liver cancer and is associated with poor prognosis | |
| US20150233930A1 (en) | Methods and compositions employing secreted proteins that reflect autophagy dynamics within tumor cells | |
| Haldar et al. | Expression of DKK1, HOXC6, and YKT6 Genes in Subjects With Oral Squamous Cell Carcinoma Residing in Central India: A Case-Control Study | |
| Gopalakrishnan et al. | SND1, a novel m6A RNA regulator: Its high expression correlates with tumorigenesis and poor prognosis in head and neck squamous cell carcinoma | |
| KR20240053637A (ko) | 개선된 암 진단 및 치료법 선택을 위한 차세대 시퀀싱 및 인공 지능-기반 접근법 | |
| WO2023244582A1 (en) | Lung cancer-related biomarkers and methods of using the same | |
| Gingras | Age at Diagnosis and Lung Cancer Presentation |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20130830 |
|
| FZDE | Discontinued |
Effective date: 20170605 |